At the news
? BULLISHIMPACT 8/10 PREM14A filed May 28, 2026 at 16:56 ET
Catalyst Pharmaceuticals (CPRX) filed a preliminary proxy statement (PREM14A) seeking stockholder approval for its acquisition by Angelini Pharma at $31.50 per share in cash, a transaction valued at approximately $4.1 billion. The board unanimously recommends the deal, which includes a 28% premium to the 30-day VWAP and follows the resolution of all FIRDAPSE patent litigation with Hetero agreeing not to launch a generic before January 2035.
- Merger consideration: $31.50 per share in cash (28% premium to 30-day VWAP, 21% premium to unaffected close of $25.94)
- Total equity value: approximately $4.1 billion
- Board unanimously recommends voting FOR the merger proposal
- J.P. Morgan fairness opinion: consideration is fair from a financial point of view
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access